ATE400261T1 - Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie - Google Patents

Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie

Info

Publication number
ATE400261T1
ATE400261T1 AT04005807T AT04005807T ATE400261T1 AT E400261 T1 ATE400261 T1 AT E400261T1 AT 04005807 T AT04005807 T AT 04005807T AT 04005807 T AT04005807 T AT 04005807T AT E400261 T1 ATE400261 T1 AT E400261T1
Authority
AT
Austria
Prior art keywords
image
radiotherapy
chemotherapy
tumor
histone deacetylase
Prior art date
Application number
AT04005807T
Other languages
English (en)
Inventor
Yih-Lin Chung
Original Assignee
Asan Lab Company Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asan Lab Company Cayman Ltd filed Critical Asan Lab Company Cayman Ltd
Application granted granted Critical
Publication of ATE400261T1 publication Critical patent/ATE400261T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04005807T 2004-03-11 2004-03-11 Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie ATE400261T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04005807A EP1574213B1 (de) 2004-03-11 2004-03-11 Verwendung von Histone Deacetylase Hemmern zur Steigerung der therapeutischen Wirkung in der Radiotherapie und Chemotherapie

Publications (1)

Publication Number Publication Date
ATE400261T1 true ATE400261T1 (de) 2008-07-15

Family

ID=34814300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04005807T ATE400261T1 (de) 2004-03-11 2004-03-11 Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie

Country Status (4)

Country Link
EP (1) EP1574213B1 (de)
AT (1) ATE400261T1 (de)
DE (1) DE602004014895D1 (de)
ES (1) ES2311763T3 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615962A2 (pt) * 2005-07-27 2011-05-31 Univ Florida uso de um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lisossomal, um inibidor do trasporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador da resposta a choque térmico, um inibidor de glicosidade, e um inibidor de histona deacetilase, uso de 11-cis-retinal ou 9-cis-retinal e um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lissosomal, um inibidor do transporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador de resposta a choque térmico, um inibidor de glicosidase, e um inibidor de histona deacetilase, método para aumentar a quantidade de um conformação bioquimicamente funcional de uma proteìna em uma célula, composição farmacêutica para o tratamento de um pcd ocular, composição farmacêutica para o tratamento de retinite pigmentosa, kit para o tratamento de um pcd ocular, kit para o tratamento de retinite pigmentosa, método para a identificação de um composto útil para o tratamento de um indivìduo que tem um pcd ocular, método para a identificação de um composto útil para o tratamento de um indivìduo que tem retinite pigmentosa, uso de um inibidor proteassomal ou um inibidor de autofagia e método para a produção de uma proteìna recombinante em uma conformação bioquimicamente funcional
EP1924245A2 (de) * 2005-08-19 2008-05-28 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Topische formulierungen von histondeacetylase-hemmern und verfahren zur verwendung derselben
WO2008003013A2 (en) * 2006-06-29 2008-01-03 Abbott Laboratories Antitumorigenic drug combination comprising an hdac inhibitor and a tsp-1 peptidomimetic
WO2008127659A2 (en) * 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
WO2008132233A1 (en) * 2007-05-01 2008-11-06 Kuros Biosurgery Ag Composition, methods and kits for prevention of adhesion
JP5468015B2 (ja) 2008-01-08 2014-04-09 アクセリア ファーマシューティカルズ 抗菌ペプチド系に対する作動薬
US20120114745A1 (en) * 2009-06-26 2012-05-10 Nam-Mew Pui Method for treating or ameliorating mucocutaneous or ocular toxicities
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
EP2698156A1 (de) * 2012-08-16 2014-02-19 Lunamed AG Phenylbutyrensäure zur Chemoprävention
KR101482086B1 (ko) * 2012-11-13 2015-01-13 인하대학교 산학협력단 히스톤 탈아세틸화효소 2의 억제제를 유효성분으로 포함하는 페이로니병의 예방 또는 치료용 조성물
CN104414967A (zh) * 2013-09-06 2015-03-18 康普药业股份有限公司 一种更昔洛韦注射液及其制备方法
EP3328372A4 (de) 2015-07-28 2019-03-20 University Of Iowa Research Foundation Zusammensetzungen und verfahren zur behandlung von krebs
EP3474879A4 (de) 2016-06-24 2020-05-06 University of Iowa Research Foundation Zusammensetzungen und verfahren zur behandlung von melanomen
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037376A (en) * 1991-10-21 2000-03-14 The United States Of America As Represented By The Department Of Health And Human Services Methods for therapy of cancer
EP0827742A1 (de) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6538030B2 (en) * 2000-09-20 2003-03-25 Yih-Lin Chung Treating radiation fibrosis
WO2002069947A2 (en) * 2001-01-12 2002-09-12 Methylgene, Inc. Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20030206946A1 (en) * 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease

Also Published As

Publication number Publication date
DE602004014895D1 (de) 2008-08-21
EP1574213A1 (de) 2005-09-14
EP1574213B1 (de) 2008-07-09
ES2311763T3 (es) 2009-02-16

Similar Documents

Publication Publication Date Title
ATE400261T1 (de) Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
WO2007055941A3 (en) Histone deacetylase inhibitors with aryl-pyrazolyl motifs
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
HN2004000150A (es) Pirazoles como inhibidores de factor de necrosis tumoral
DK1591109T3 (da) Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
DE602004019229D1 (de) Inhibitoren von mitotischem kinesin
EA201071268A1 (ru) СПОСОБ ЛЕЧЕНИЯ РАКА С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА cMET И AXL И ИНГИБИТОРА erbB
NO20061319L (no) 5-arylpyrimidiner som anticancer legemidler
ATE446094T1 (de) Mitotische kinesin-hemmer
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
YU61402A (sh) Pirol substituisani 2 indolinon protein kinazni inhibitori
BR112022020817A2 (pt) Inibidores de kif18a para tratamento de doenças neoplásicas
RU2008124827A (ru) Лечение нейроэндокринных опухолей
WO2009005638A3 (en) Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
EA201000620A1 (ru) Ингибиторы csf-1r, предназначенные для лечения рака и заболеваний костей
EA201290451A1 (ru) Способ лечения фибрилляции предсердий
WO2007070372A3 (en) Compositions and methods for inhibiting cellular proliferation
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
MX2022010512A (es) Inhibidores de proteína bcl-2.
MX2022000310A (es) Inhibidores de proteina bcl-2.
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
EA202192528A1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
Yavas et al. The effect of Halofuginone in the amelioration of radiation induced-lung fibrosis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties